Coherus BioSciences (CHRS) revenue breakdown
By product, Toripalimab is the largest at 97% of fiscal 2025 revenue, growing 759% a year over 2 years.
Revenue by product
Fiscal years, as Coherus BioSciences reports them in its 10-K filings; fiscal 2025 total $42M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Toripalimab | — | — | $554,000 | $19M | $41M | 97% |
| Other revenue | $42,000 | $282,000 | $664,000 | $7M | $1M | 3% |
| Total net product revenue | $327M | — | — | — | — | — |
| UDENYCA | — | $204M | $127M | — | — | — |
| CIMERLI | — | $7M | $125M | — | — | — |
| YUSIMRY | — | — | $4M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CHRS.
Open CHRS in InvestinglyQuestions
Where does Coherus BioSciences make its money?
In fiscal 2025, by product: Toripalimab $41M, Other revenue $1M.
From Coherus BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.